Synairgen plc (SYGGF) Research

Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD). Furthermore, Synairgen is developing a LOXL2 inhibitor specifically for idiopathic pulmonary fibrosis (IPF) disease. This LOXL2 inhibitor is being developed through a licensing and collaborative agreement with Pharmaxis Ltd. The company was founded in 2004 and is based in Southampton, United Kingdom.

Market snapshot

Symbol
SYGGF
Price
$0.00
Day change
0.00%
Market cap
$11.6M
P/E ratio
-0.23x
52-week range
0.00001-0.0141
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • AccuStem Sciences Limited (ACMSY)
  • Cell Source, Inc. (CLCS)
  • Gemina Laboratories Ltd. (GLABF)
  • Immunovia AB (publ) (IMMVF)
  • EOM Pharmaceuticals Holdings, Inc. (IMUC)
  • Propanc Biopharma, Inc. (PPCB)
  • Quest PharmaTech Inc. (QPTFF)
  • Sirona Biochem Corp. (SRBCF)

Open Synairgen plc (SYGGF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.